Legal Representation
Attorney
Ilene B. Tannen
USPTO Deadlines
Application History
16 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 2, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jan 1, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| May 30, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 4, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 4, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 15, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 1, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 2, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 1, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 1, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 9, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 4, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 6, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 4, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the prevention and treatment of cancer, retinal, liver, metabolic, autoimmune, cardiovascular, neurological, immune, musculoskeletal, endocrine and hematological diseases and disorders
Class 042
Providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Class 044
Providing medical information relating to cancer, retinal diseases and liver and metabolic diseases
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOPHARMACEUTICALS"